OTR-012

OTR-012 is a preclinical-stage therapeutic candidate being developed by OTR Therapeutics in collaboration with Zealand Pharma for the treatment of obesity and cardiometabolic diseases. The drug utilizes OTR Therapeutics' proprietary ReGeneraTing Agent (RGTA) technology, which consists of engineered polymers designed to mimic heparan sulfates. These agents function by binding to and protecting endogenous signaling proteins, such as growth factors and cytokines, from proteolytic degradation within the extracellular matrix. By stabilizing these proteins, OTR-012 aims to restore metabolic homeostasis and promote tissue repair. While the specific molecular target remains undisclosed, the partnership leverages Zealand Pharma's specialized expertise in peptide therapeutics to address metabolic disorders.